Scarica l'app Stockscreener
156.57
0.92%
1.43
Dopo l'orario di chiusura:
156.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$155.14
Aprire:
$154.38
Volume 24 ore:
895.19K
Relative Volume:
0.74
Capitalizzazione di mercato:
$15.92B
Reddito:
$3.10B
Utile/perdita netta:
$668.60M
Rapporto P/E:
24.07
EPS:
6.5044
Flusso di cassa netto:
$831.30M
1 W Prestazione:
-1.12%
1M Prestazione:
-5.06%
6M Prestazione:
+20.57%
1 anno Prestazione:
+10.85%
Intervallo 1D:
$152.04
$159.94
Intervallo di 1 settimana:
$151.77
$159.94
Portata 52W:
$122.14
$186.12
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
156.57 | 15.77B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 58.15B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.35 | 42.94B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.29B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.86 | 21.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Australia
Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08 - marketscreener.com
Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Canada
Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com Canada
Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026 - Stock Titan
Neurocrine Biosciences at Wells Fargo conference: growth story broadens - Investing.com
Neurocrine Biosciences stock rating reaffirmed by RBC Capital - Investing.com
How Advancing NBI-1117567 to Phase 2 and a $10M Milestone Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 36% Upside Potential with Robust Revenue Growth - DirectorsTalk Interviews
Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run - simplywall.st
Neurocrine (NBIX) director donates 1,000 shares - Stock Titan
Neurocrine Biosciences Inc. (NBIX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Boston and New York are stops for Neurocrine’s three September healthcare talks. - Stock Titan
Neurocrine Biosciences (NBIX) Institutional Ownership 2026 - MarketBeat
Resilient Neurocrine Biosciences stock holds firm as Crenessity sales surge and valuation stretches - AD HOC NEWS
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX): An Affordable Growth Stock With Strong Momentum and Valuation - ChartMill
Neurocrine Biosciences (NBIX) Cleared An FDA Milestone, Is It Trading At A Discount? - simplywall.st
How Investors May Respond To Neurocrine Biosciences (NBIX) Phase 4 INGREZZA Patient-Reported Benefit Data - Sahm
Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative? - Yahoo Finance
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND - globenewswire.com
Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run - simplywall.st
Neurocrine Biosciences: 'House Full Of Options' - Seeking Alpha
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Yahoo Finance
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? - Yahoo Finance
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - Yahoo Finance Singapore
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data - simplywall.st
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
GlobesIsrael Business News - גלובס
Neurocrine Biosciences Rings the Nasdaq Stock Market Opening Bell - Nasdaq
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? - Yahoo Finance
Neurocrine Biosciences Rings the Opening Bell - Nasdaq
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: 38.54% Potential Upside Beckons Investors - DirectorsTalk Interviews
Neurocrine Biosciences (HAM:NB3) Cyclically Adjusted Price-to-FCF : (As of Aug. 16, 2026) - GuruFocus
S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V. - MarketBeat
Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership? - simplywall.st
NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths - The Business Journals
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Neurocrine Biosciences Inc (NBIX) Shares Fall 3.6% -- What GF Sc - GuruFocus
Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy - insights.citeline.com
Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Yahoo Finance
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.73%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):